Table A1.

International Pediatric Renal Tumor Biology Conferences

Meeting	Location and Year	Major Themes
1	Albuquerque, NM, 1992	Tumor banking; first 120 cases in Pediatric Oncology Group Tumor Bank Cytogenetic changes in Wilms tumor Early studies of loss of heterozygosity at 11p, 1p, and 16q WT1 expression and correlation with histology
2	Philadelphia, PA, 1995	WT1 mutations in bilateral Wilms tumor 11p15 alterations in Wilms tumor and Beckwith-Wiedemann syndrome Cytogenetic changes in Wilms tumor
3	Philadelphia, PA, 1997	FWT1 as a familial Wilms tumor locus Large-scale studies of LOH 1p and 16q as a prognostic marker
4	London, United Kingdom, 2002	WT1-based immunotherapy Early studies of gene expression profiles in Wilms tumor New genes/loci in Wilms tumor: HACE1, chromosome 7p
5	Vancouver, British Columbia, Canada, 2005	Array comparative genomic hybridization (CGH) and more gene expression profiles
6	Chamonix, France, 2008	New genes/loci: WTX Interactions between WT1, CTNNB1, and WTX in Wilms tumorigenesis Animal models: mice, zebrafish, rats Novel therapeutic targets: Stat pathway, IGF
7	Banff, Alberta, Canada, 2010	WT1 in Wilms tumor development: collaboration with Wnt signaling, Igf2 Association between 1q gain, 1p loss, 16q loss, and relapse New genes in Wilms tumor: FBXW7, MYCN Novel therapeutic targets: MTOR pathway, telomerase, IGF
8	Bethesda, MD, 2013	Wilms tumor stem cells; CD56 as a therapeutic target Large-scale studies confirming 1q gain as a prognostic factor Aneuploidy and TP53 mutations in anaplastic Wilms tumor DICER1 mutations in renal tumors and deregulation of microRNA Novel therapeutic targets: results from Pediatric Pre-Clinical Testing Program Urine and serum proteomics Biology of pediatric renal cell carcinoma

Abbreviation: IGF, insulin-like growth factor.